Canada: New Use Patent For Janssen's REMICADE Valid And Infringed By Hospira's Biosimilar INFLECTRA

On March 7, 2018, the Federal Court upheld the validity of Kennedy's patent for a use of infliximab (Janssen's REMICADE) (Patent No. 2,261,630 [the "630 patent"]), and granted Kennedy's counterclaim that Hospira's biosimilar INFLECTRA infringed the 630 patent: Hospira Healthcare Corporation v Kennedy Trust for Rheumatology Research, 2018 FC 259

Infliximab is an antibody that inhibits binding at TNF-α receptors, a key target in autoimmune diseases. Janssen's infliximab product, REMICADE, is approved for use in combination with methotrexate (MTX) for the treatment of rheumatoid arthritis (RA).  In broad terms the 630 patent claims use of the combination of infliximab with MTX for the treatment of RA in patients whose disease was not controlled by previous MTX treatment alone.

MTX was a commonly used treatment for RA, and studies had been published that established infliximab could provide rapid and significant relief of RA symptoms, though the duration of the effect was limited. The inventors of the 630 patent found that a combination of MTX and infliximab led to a sustained duration of response and enhanced efficacy over MTX or infliximab alone.

Justice Phelan addressed Hospira's arguments on "an astonishing number and veritable panoply of patent law issues," including standing, claim construction, various grounds of invalidity and infringement, both direct and induced.

Standing: All of the named plaintiffs were held to have standing to bring the action for infringement. Justice Phelan rejected Hospira's argument of improper assignment to a different Kennedy entity, holding that any mistake made in filing the patent was later rectified, and Kennedy Trust is the owner of the patent. The standing of the remaining parties (Janssen Canada, Janssen US, and Cilag) was established on the basis that they were licensees/sublicensees of the patent.

Skilled person: The parties disputed the qualifications of the skilled person to whom the 630 patent was addressed. Reasoning that the skilled person must not be imbued with extraordinary levels of skill and experience, nor a cutting edge expert, Justice Phelan held the skilled person was a rheumatologist or team who treated patients, and could also include a post-doctorate level biologist or molecular biochemist with experience with monoclonal antibodies.

Claim Construction: Hospira's proposed claim construction limited the claimed 'infliximab' molecule to the exact molecule described in the patent, and therefore excluded CT-P13 (INFLECTRA) in view of differences in glycosylation. Justice Phelan instead accepted the patentee's construction, holding that the skilled person would understand that infliximab is defined by its amino acid sequence, as this gives the antibody the defining characteristics of high affinity, neutralization and binding to a TNF-α.


The Court dismissed Hospira's validity attacks, including method of medical treatment, overbreadth, double patenting, insufficiency and the unknown attack of "improper priority". The Court also assessed the following grounds of invalidity:

Novelty: The Court rejected Hospira's arguments.

  • The asserted prior art documents suggested trying infliximab or anti-TNF α antibody in combination with MTX, or referenced clinical trials where that combination was being tried. The Court agreed with Kennedy that the publications were speculative and only suggested avenues for future research without any reason to expect success, or providing any enabling detail (some did not specify infliximab). The Court held that the prior art publications did not disclose the special advantage of the invention, which the Court held was a reduced human anti-chimeric antibodies response and improved pharmacokinetics enabling long-term treatment of infliximab with good efficacy and tolerability.
  • The Court held that clinical trial patient consent forms for one of the trials exemplified in the patent do not anticipate the claims as they are covered under the experimental use exception to anticipation, the forms were confidential, and finding otherwise would be contrary to public policy (may lead to an end to informed consent or the patenting of medication).

Obviousness: As a result of disagreement between the parties on the inventive concept, the Court considered "what is claimed in the patent" and identified the inventive concept as (1) the manufacture of a medicament using and (2) a pharmaceutical composition containing: an anti-human TNF-α antibody that can be used in combination with MTX in the treatment of RA. While the state of the art disclosed the use of each of MTX and infliximab to treat RA, the combination was only suggested in a speculative manner. The Court held it was reasonable to carry out combination trials, but it was not obvious to do so. The mechanism of action of the drugs and treatment of RA were not well-understood, and the prior art contained no indication that the combination was to be preferred or that it would solve the problem of shortened response to treatment that was identified in the prior art. In addition, despite a great deal of motivation to develop a new treatment for RA, others did not try the solution of the patent, instead solutions were being pursued in a number of different ways with other biologics (most of which failed).

Utility/promise: The experts agreed that the 630 patent had a scintilla of utility, including giving a new and useful choice to treat RA, and this was sufficient utility given the Supreme Court of Canada's decision in AstraZeneca ( previously reported). Justice Phelan rejected Hospira's attempt to import the discarded "promise" doctrine into insufficiency and overbreadth.


Justice Phelan concluded Hospira infringed the patent, both directly and by inducing patients:

Direct infringement: The Court found that the essential elements of the asserted claims were infringed. Hospira's infliximab product was covered by the claims: there was no material difference in glycosylation, and while the infliximab in INFLECTRA has a single additional amino acid at the C-terminal, this was known by the skilled person to have no impact on function.

The Court also rejected Hospira's argument that it did not produce infliximab in combination with MTX for the treatment of RA, and in relation to the Swiss-type claims, despite manufacture abroad, Hospira was still liable for infringement under the Saccharin doctrine.

Inducing infringement: The Court found that Hospira induced infringement in patients: there was direct infringement by third parties and Hospira's product monograph amounted to instructions for infringement.


This is the third patent infringement action decision relating to a biologic (after Kirin-Amgen Inc v Hoffmann-La Roche Ltd (1999), 87 CPR (3d) 1, relating to erythropoietin and AbbVie Corporation v Janssen Inc, 2014 FC 55, set aside 2014 FCA 242, relating to ustekinumab/STELARA). It is only the second decision on the merits relating to a biosimilar (the first was in an application under the pre-amended PMNOC Regulations relating to filgrastim, previously reported here). As reported here, there are a number of patent litigation matters relating to biosimilars in progress, including infringement/impeachment actions and applications under the pre-amended PMNOC Regulations and more recently, under the amended PMNOC Regulations. Hospira may appeal as of right.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Urszula Wojtyra
In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions